CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • May 10th, 2022 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of March 9, 2022 (the “Effective Date”), is by and between IDEAYA Biosciences, Inc., having a place of business at 7000 Shoreline Ct, Suite 350, South San Francisco CA 94080 (“Ideaya”), and Pfizer Inc., having a place of business at 235 East 42nd Street, New York, NY 10017 USA (“Pfizer”). Ideaya and Pfizer are each referred to herein individually as “Party” and collectively “Parties”.
Amendment No. 2 to Collaboration, Option and License AgreementCollaboration, Option and License Agreement • May 10th, 2022 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment No. 2”) to the Collaboration, Option and License Agreement entered into as of June 15, 2020 between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (“GSK”), a company registered in England and Wales (registered number 11721880), and IDEAYA Biosciences, Inc., (“IDEAYA”) a Delaware corporation having an office at 7000 Shoreline Court, Suite 350, South San Francisco, CA 94080, as amended by the Amendment No. 1 effective as of October 23, 2020 (the “Agreement”) is effective as of January 31, 2022 (“Amendment No. 2 Effective Date”). GSK and IDEAYA are sometimes referred to individually as a “Party” and collectively as the “Parties.”
